Index by category›
Research area
Approved non-peptide medicines
Defined small-molecule medicines that appeared in the source peptide catalog but must be classified and read as non-peptides.
This area keeps a critical identity distinction visible: inclusion in an external peptide catalog does not make a compound a peptide.
Tadalafil is a defined non-peptide small-molecule PDE5 inhibitor with product- and jurisdiction-specific approvals for erectile dysfunction, BPH symptoms and pulmonary arterial hypertension. Approval applies to authorised products and specific indications; it is not evidence for general libido, testosterone, weight-loss or vascular-health claims.
Ezetimibe is a defined non-peptide small-molecule cholesterol-absorption inhibitor with authorised lipid-lowering uses. Its main cardiovascular outcome evidence must remain tied to the studied regimen and population: IMPROVE-IT added ezetimibe to simvastatin after acute coronary syndrome, while EWTOPIA 75 was an open-label Japanese primary-prevention study in adults aged 75 years or older.
Approval does not remove interaction risk
Tadalafil is contraindicated with organic nitrates and with guanylate-cyclase stimulators such as riociguat. Product, indication, cardiovascular status and other medicines require clinical review.
Lipid lowering is not a universal outcome claim
Ezetimibe lowers LDL-C, but combination results cannot be rewritten as monotherapy, weight-loss or longevity evidence. Statins, fibrates, cyclosporine and bile-acid sequestrants add product-specific safety and interaction boundaries.
2 peptides studied in this area
Tadalafil
Cialis
Tadalafil is a prescription PDE5 inhibitor—not a peptide—with regulator-approved uses for erectile dysfunction, benign prostatic hyperplasia and, under separate products, pulmonary arterial hypertension. Its long half-life and established efficacy sit beside important cardiovascular interactions, especially an absolute contraindication with nitrates or riociguat.
Ezetimibe
Zetia
Ezetimibe is an approved oral small-molecule medicine—not a peptide—that lowers LDL cholesterol by inhibiting intestinal NPC1L1-mediated sterol absorption. Product approval and outcome evidence are indication- and combination-specific: IMPROVE-IT tested ezetimibe added to simvastatin after acute coronary syndrome, not ezetimibe as a weight-loss or longevity monotherapy.